Search

Search Results

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4383

  PDF: 1618

  HTML: 3578

  Tables and Images: 213

• BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT IN SPLENIC MARGINAL ZONE LYMPHOMAS of ELDERLY PATIENTS.

  Roberto Castelli

  e2016030

  2016-07-01

  https://doi.org/10.4084/mjhid.2016.030

  4315

  PDF: 974

  HTML: 1660

• Severe CMV infection after chemo-immunotherapy with dose- reduced bendamustine and rituximab in an old mantle cell lymphoma patient

  Gabriele Magliano, Annarosa Cuccaro, Francesco D'Alo', Elena Maiolo, Silvia Bellesi, Stefan Hohaus, Andrea Bacigalupo, Livio Pagano

  e2021054

  2021-08-28

  https://doi.org/10.4084/MJHID.2021.054

  1202

  PDF: 390

  HTML: 138

• WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE

  Maddalena Mazzucchelli, Anna Maria Frustaci, Marina Deodato, Roberto Cairoli, Alessandra Tedeschi

  e2018004

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.004

  7387

  PDF: 2404

  HTML: 1715

  Table 1.: 201

  Table 2.: 213

  Table 3.: 194

  Table 4.: 194

• CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA

  Luca Castagna, Carmelo Carlo-Stella, Rita Mazza, Armando Santoro

  e2015015

  2015-02-12

  https://doi.org/10.4084/mjhid.2015.015

  2762

  PDF: 1405

  HTML: 4608

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4011

  PDF: 1137

  HTML: 1925

  Fig.1: 213

  Fig. 2: 105

  Table 1: 199

  Table2: 215

  Table 3: 196

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  4280

  PDF: 1474

  HTML: 1539

  Untitled: 221

• WALDENSTRÖM MACROGLOBULINEMIA - A STATE-OF-THE-ART REVIEW: PART 2- FOCUS ON THERAPY

  Michele Bibas, Shayna Sarosiek , Jorge Castillo

  e2025015

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.015

  2463

  PDF: 1967

  HTML: 194

• INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  AnnaMaria Nosari

  e2012070

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.070

  3257

  PDF: 1335

  HTML: 2618

• HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?

  Antoine Thyss, Esma Saada, Lauris Gastaud, Frédéric Peyrade, Daniel Ré

  e2014050

  2014-07-01

  https://doi.org/10.4084/mjhid.2014.050

  2859

  PDF: 1351

  HTML: 3561

  Untitled: 188

  Untitled: 198

  Untitled: 173

• BING-NEEL SYNDROME: ILLUSTRATIVE CASES AND COMPREHENSIVE REVIEW OF THE LITERATURE

  Marzia Varettoni, Irene Defrancesco, Luca Diamanti, Enrico Marchioni, Lisa Maria Farina, Anna Pichiecchio

  e2017061

  2017-10-18

  https://doi.org/10.4084/mjhid.2017.061

  3400

  PDF: 1469

  HTML: 1278

• INVASIVE FUNGAL INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS IN THE ERA OF TARGET DRUGS

  Livio Pagano, Davide Facchinelli, Dr.

  e2018063

  2018-10-27

  https://doi.org/10.4084/mjhid.2018.063

  1997

  PDF: 1107

  HTML: 174

• NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL

  Dimitar Efremov, Adrian Wiestner, Luca Laurenti

  e2012067

  2012-10-09

  https://doi.org/10.4084/mjhid.2012.067

  2461

  PDF: 832

  HTML: 8803

  Efremov 1: 219

  Efremov 2: 180

• RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: CHEMOIMMUNOTHERAPY, TREATMENT UNTIL PROGRESSION WITH MECHANISM-DRIVEN AGENTS OR FINITE-DURATION THERAPY?

  Antonio Cuneo, Robin Foà

  e2019024

  2019-02-27

  https://doi.org/10.4084/mjhid.2019.024

  2655

  PDF: 1641

  HTML: 251

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS

  Giuseppe Visani, Paola Picardi, Patrizia Tosi, Alessandro Isidori

  e2012075

  2012-11-07

  https://doi.org/10.4084/mjhid.2012.075

  2500

  PDF: 864

  HTML: 2116

• GREEK CONSENSUS ON CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATMENT

  Sotirios Sachanas, Theodoros Vassilakopoulos, Maria Angelopoulou, sotirios Papageorgiou, Emmanouil Spanoudakis, Maria Bouzani, Maria Dimou, Panagiotis Panagiotidis

  e2025014

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.014

  1310

  HTML: 118

  PDF: 852

• BCR SIGNALING INHIBITORS: AN OVERVIEW OF TOXICITIES ASSOCIATED WITH IBRUTINIB AND IDELALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

  Lorenzo Falchi, Jessica M Baron, Carrie Anne Orlikowski, Alessandra Ferrajoli

  e2016011

  2016-02-10

  https://doi.org/10.4084/mjhid.2016.011

  4278

  PDF: 1472

  HTML: 3607

• IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?

  Giuseppe Gritti, Chiara Pavoni, Alessandro Rambaldi

  e2017010

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.010

  3339

  PDF: 1271

  HTML: 2207

  Fi.1 Gritti.Rambaldi: 201

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  1671

  PDF: 1645

  HTML: 785

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3701

  PDF: 1052

  HTML: 1917

• BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.

  Stefano Molica

  e2025053

  2025-06-29

  https://doi.org/10.4084/MJHID.2025.053

  1521

  PDF: 877

  HTML: 106

• CHLORAMBUCIL PLUS RITUXIMAB AS FRONT-LINE THERAPY IN ELDERLY/UNFIT PATIENTS AFFECTED BY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF A SINGLE-CENTRE EXPERIENCE.

  Luca Laurenti, Barbara Vannata, Idanna Innocenti, Francesco Autore, Francesco Santini, Nicola Piccirillo, Tommaso Za, Silvia Bellesi, Sara Marietti, Simona Sica, Dimitar G. Efremov, Giuseppe Leone

  e2013031

  2013-05-01

  https://doi.org/10.4084/mjhid.2013.031

  3122

  PDF: 885

  HTML: 1528

  Fig.1 CHL-R paper: 209

  Fig 2 CHL-R paper: 232

• AUTOLOGOUS STEM CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA STILL A VALID TREATMENT OPTION, OR IS THE GAME OVER ?

  Fabienne McClanahan, Peter Dreger

  e2012071

  2012-11-06

  https://doi.org/10.4084/mjhid.2012.071

  2397

  PDF: 803

  HTML: 1657

• CHRONIC LYMPHOCYTIC LEUKAEMIA: CENSUS OF PATIENTS TREATED IN ITALIAN HAEMATOLOGY UNITS

  Gianfranco Salvi

  e2015056

  2015-10-18

  https://doi.org/10.4084/mjhid.2015.056

  1434

  PDF: 963

  HTML: 1898

• Impact of Sars-CoV-2 prophylaxis with tixagevimab-cilgavimab in high-risk patients with B-cell malignancies: a single-center retrospective study.

  Giovanni Manfredi Assanto ,, Matteo Totaro , Poggiali Rebecca, Delli Paoli Adele, Annechini Giorgia, D’Elia Gianna Maria, Aji Francesco, Petrucci Luigi, Fazio Francesca, Del Giudice Ilaria, Martelli Maurizio, Micozzi Alessandra, Giuseppe Gentile

  e2023061

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.061

  765

  PDF: 408

  HTML: 107

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1524

  PDF: 1186

  HTML: 175

• TUBERCULOSIS IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

  Luis Anibarro, Alberto Pena

  e2014026

  2014-04-06

  https://doi.org/10.4084/mjhid.2014.026

  3218

  PDF: 1228

  HTML: 8098

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1537

  PDF: 596

  HTML: 180

• Orbital Infiltration in a Patient with Waldenström Macroglobulinemia: Need for Multidisciplinary Approach and Comparison with the Literature

  Riccardo Paggi, Francesca Mariotti, Jessica Mencarini, Silvia Bresci, Irene Capolmi, Filippo Bartalesi, Beatrice Borchi, Luca Nassi, Alessandro Maria Vannucchi, Alessandro Bartoloni

  e2023028

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.028

  959

  PDF: 749

  HTML: 327

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1641

  PDF: 640

  HTML: 2423

• THE START-UP OF THE FIRST HEMATOPOIETIC STEM CELL TRANSPLANTATION CENTER IN THE IRAQI KURDISTAN: A CAPACITY-BUILDING COOPERATIVE PROJECT BY THE HIWA CANCER HOSPITAL, SULAYMANIYAH, AND THE ITALIAN AGENCY FOR DEVELOPMENT COOPERATION

  Ignazio Majolino

  e2017031

  2017-04-15

  https://doi.org/10.4084/mjhid.2017.031

  2229

  PDF: 996

  HTML: 2071

• An Urologic Face of Chronic Lymphocytic Leukemia:Sequential Prostatic and Penis Localization

  Giovanni D'Arena, Roberto Guariglia, Oreste Villani, Maria Carmen Martorelli, Giuseppe Pietrantuono, Giovanna Mansueto, Giuseppe Patitucci, Emilio Imbriani, Tommaso Masciandaro, Ludovica Borgia, Giulia Vita, Fiorella D'Auria, Teodora Statuto, Pellegrino Musto

  e2013008

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.008

  1514

  PDF: 1095

  HTML: 2949

• Response to ibrutinib of a refractory IgA lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation

  Francesca Maria Quaglia, Gian Matteo Rigolin, Elena Saccenti, Massimo Negrini, Eleonora Volta, Melissa Dabusti, Maria Ciccone, Antonio Urso, Michele Laudisi, Antonio Cuneo

  e2019057

  2019-08-29

  https://doi.org/10.4084/mjhid.2019.057

  1530

  PDF: 949

  HTML: 239

• OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT

  Ulrike Bacher, Stefanie von Matt, Yara Banz, Behrouz Mansouri, Urban Novak, Thomas Pabst

  e2023025

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.025

  1272

  HTML: 294

  PDF: 924

  Suppl. Files: 440

• “IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”

  Sara Martinelli, Antonio Cuneo, Gian Matteo Rigolin

  e2016047

  2016-10-15

  https://doi.org/10.4084/mjhid.2016.047

  3977

  PDF: 1037

  HTML: 3575

  Untitled: 172

  Cneo. Fig.1: 108

  Untitled: 98

  Untitled: 123

  Untitled: 127

• Achieving the cure of follicular lymphoma: is it time to finalize treatment strategies to reach this goal in a subset of patients?

  Mauro Passucci, Giovanni Assanto, Alessandro Pulsoni

  e2023018

  2023-02-28

  https://doi.org/10.4084/MJHID.2023.018

  1100

  PDF: 895

  HTML: 347

• COINCIDENCE OR CONNECTION? REVISITING THE RELATIONSHIP BETWEEN MASTOCYTOSIS AND LYMPHOMA

  Antonio Frolli, Cristina Papayannidis, Carmen Fava, Martina Bullo, Selene Grano, Valentina Bonuomo, Daniela Gottardi, Guido Parvis, Beatrice Casadei, Daniela Cilloni

  e2026047

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.047

  115

  PDF: 129

  HTML: 8

• Coexistence of T-Large Granular Lymphocyte Leukemia and Peripheral T Cell Lymphoma-NOS with indolent behaviour

  Luca Guarnera, Valentina Boldrini, Gianmario Pasqualone, Carolina Cimino, Elisa Meddi, Roberta Laureana, Donata Trivigno, Giovanni Del Poeta, Alessandro Mauriello, Lucia Anemona, Massimiliano Postorino, Maria Cantonetti

  e2022006

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.006

  1607

  PDF: 594

  HTML: 308

• CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma

  Ugo Testa, Francesco D'Alò, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2024012

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.012

  2231

  PDF: 1803

  HTML: 133

• Pathogenetic mechanism of macular edema during a treatment with ibrutinib: a case presentation.

  Cristina Mauro, Livio Pupo, Lucia Cardillo, Fabiana Esposito, Elisa Buzzatti, Marco Lombardo, Massimo Cesareo, Adriano Venditti, Massimiliano Postorino, Maria Ilaria Del Principi

  e2026009

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.009

  525

  PDF: 398

  Html: 286

• TREATMENT OUTCOMES AND CLINICAL RELEVANCE IN PATIENTS WITH DOUBLE EXPRESSOR DLBCL Sirapat Rungwittayatiwat1, Paisarn Boonsakan2, Pichika Chantrathammachart1, Teeraya Puavilai1, Sulada Pukiat1, Sithakom Phusanti1,3, Kochawan Boonyawat1, Pathawut Wacharapornin1, Pantep Angchaisuksiri1, Artit Ungkanont1,3, Suporn Chuncharunee1 Pimjai Niparuck1

  PIMJAI NIPARUCK

  e2021063

  2021-10-29

  https://doi.org/10.4084/MJHID.2021.063

  1105

  PDF: 502

  HTML: 176

• A rare immune-related mesenteric and retroperitoneal serositis in a multirefractory Hodgkin lymphoma patient successfully treated with chylolymphostatic surgery

  Matteo D'Addona, Luca Pezzullo, Corradino Campisi, Corrado Cesare Campisi, Valentina Giudice, Vincenzo Ciccone, Roberto Guariglia, Bianca Serio, Carmine Selleri

  e2023063

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.063

  651

  PDF: 395

  HTML: 128

• HEAVY-CHAIN DISEASES AND MYELOMA-ASSOCIATED FANCONI SYNDROME: AN UPDATE

  Roberto Ria, Franco Dammacco, Angelo Vacca

  e2018011

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.011

  5104

  PDF: 1616

  HTML: 1355